Aneuploidy plays a significant role in adverse human health conditions
including birth defects, pregnancy wastage and cancer. Although there
is clear evidence of chemically induced aneuploidy in experimental sy
stems, to date there are insufficient data to determine with certainty
if chemically induced aneuploidy contributes to human disease. Howeve
r, since there is no reason to assume that chemically induced aneuploi
dy will not occur in human beings, it is prudent to address the aneuge
nic potential of chemicals in the safety assessment process. A wide ra
nge of methods has been described for the detection of chemically indu
ced aneuploidy including subcellular systems, tests with fungi, plants
and Drosophila as well as in vitro mammalian systems and in vivo mamm
alian somatic and germ cell assays. However, none of these methods is
sufficiently validated or widely used in routine screening. Underlying
the efforts to develop aneuploidy-specific assays is the presumption
that current genetic toxicology tests do not detected chemicals that h
ave aneuploidy-inducing potential. To address this, we have critically
evaluated data from standard genetic toxicology assays for 16 known o
r suspected aneugens. The conclusions from the review are listed below
. 1. At present there are only nine chemicals that can be classified a
s definitive aneugens, as determined by positive results in in vivo ro
dent assays. 2. As expected, the majority of definitive and suspected
aneugens are negative in the bacterial mutation assay. 3. The majority
of definitive aneugens evaluated induce polyploidy in vitro. With few
exceptions, they also induced structural chromosome aberrations in vi
tro. 4. All of the definitive aneugens that have been sufficiently tes
ted induce micronuclei in rodent bone marrow cells in vivo. A number o
f these chemicals also induced structural chromosome aberrations in vi
vo. 5. There is no evidence for a unique germ cell aneugen, that is a
chemical that induces aneuploidy in germ cells and not in somatic cell
s. Furthermore, an analysis of several databases indicates the proport
ion of chemicals which induce polyploidy and not chromosome aberration
s in vitro is low. Based on these conclusions, the following recommend
ations are made: for screening purposes, a standard genotoxicity test
battery (including an in vitro cytogenetic assay with an assessment of
polyploidy and clastogenicity at the same harvest time) should be per
formed; in the absence of polyploidy induction in vitro no further eva
luation of aneuploidy-inducing potential is needed; if polyploidy is o
bserved, in vitro follow-up testing to investigate further the aneuplo
idy-inducing potential should be conducted; such follow-up testing wil
l generally start with the conduct of a standard in vivo somatic cell
micronucleus assay; if the in vivo somatic cell micronucleus assay is
negative, with adequate evidence of exposure of the bone marrow to the
test compound, no further testing of aneuploidy-inducing potential is
needed; if the in vivo somatic cell micronucleus assay is positive, f
urther information on mechanisms of micronucleus induction can be obta
ined by using kinetochore/centromeric staining in vitro and/or in vivo
; an assessment of potential germ cell aneuploidy activity may then be
considered; aneuploidy induction which does not involve the direct in
teraction of a chemical or its metabolite(s) with DNA is expected to h
ave a threshold. This must be considered in the risk assessment of suc
h chemicals; this is not addressed by current risk assessment guidelin
es. (C) 1998 Elsevier Science B.V.